|
gptkbp:instanceOf
|
gptkb:anxiolytic_drug
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:Russia
|
|
gptkbp:ATCCode
|
N05BX
|
|
gptkbp:brand
|
gptkb:Afobazol
|
|
gptkbp:CASNumber
|
173352-39-1
|
|
gptkbp:chemicalClass
|
5-ethoxy-2-[2-(morpholino)ethylthio]benzimidazole dihydrochloride
|
|
gptkbp:compatibleWith
|
gptkb:antidepressant
gptkb:European_Union
gptkb:United_States
gptkb:benzodiazepine
muscle relaxation
sedation
dependence
|
|
gptkbp:contraindication
|
pregnancy
lactation
children under 18
|
|
gptkbp:developedBy
|
gptkb:Russia
|
|
gptkbp:discoveredBy
|
Russian scientists
|
|
gptkbp:form
|
tablets
|
|
gptkbp:hasNo
|
international nonproprietary name (INN)
|
|
gptkbp:legalStatus
|
prescription only (Russia)
|
|
gptkbp:marketedAs
|
2001
OTCPharm
|
|
gptkbp:mechanismOfAction
|
modulation of GABA receptors
modulation of sigma-1 receptors
selective anxiolytic effect
|
|
gptkbp:notControlledSubstance
|
gptkb:Russia
most countries
|
|
gptkbp:prescriptionStatus
|
prescription only (Russia)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
allergic reactions
gastrointestinal upset
|
|
gptkbp:usedFor
|
gptkb:adjustment_disorder
gptkb:alcohol_withdrawal_syndrome
gptkb:generalized_anxiety_disorder
sleep disorders
smoking cessation
anxiety disorders
neurasthenia
asthenic disorders
somatic disorders
|
|
gptkbp:bfsParent
|
gptkb:Pharmstandard
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Afobazol
|